Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Zerion Pharma Aps has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, indicating that the portfolio spans separate examination settings.
PARK, HAEJIN S is the busiest examiner, with 1 pending office action. Counsel should treat the matters independently while using the technology area to maintain consistent substantive positions where appropriate.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| SASAN, ARADHANA | 1 | 64.6% | +26.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564552 | CO-AMORPHOUS FORMS FOR USE IN CANCER THERAPY | SASAN, ARADHANA | 113d overdue |
| 18713118 | TERNARY CO-AMORPHOUS FORMS OF DRUGS, PROTEINS, AND WATER-SOLUBLE POLYMERS | PARK, HAEJIN S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18713118 | TERNARY CO-AMORPHOUS FORMS OF DRUGS, PROTEINS, AND WATER-SOLUBLE POLYMERS | PARK, HAEJIN S | 1614 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18564552 | CO-AMORPHOUS FORMS FOR USE IN CANCER THERAPY | SASAN, ARADHANA | 1615 | §103§112DP | Final Rejection | 113d overdue | Pending | Nov 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZerion Pharma Aps has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Haejin S Park has the most, with 1 of Zerion Pharma Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
